The Importance of Unresolved Fatigue in Depression: Costs and Comorbidities

Psychosomatics

Volumn 56, Issue 3, 2015, Pages 274-285

  Robinson, Rebecca L ^a   Stephenson, Judith J ^b   Dennehy, Ellen B ^a,c   Grabner, Michael ^b   Faries, Douglas ^a   Palli, Swetha Rao ^b   Swindle, Ralph W ^a  

^a ELI LILLY AND COMPANY   (United States)

^b HEALTHCORE INC   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; HYPNOTIC AGENT; MOOD STABILIZER; STEROID;

ADULT; ANXIETY; ARTICLE; ATHENS INSOMNIA SCALE; BRIEF PAIN INVENTORY; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; COMORBIDITY; DEMOGRAPHY; DEPRESSION; DISEASE SEVERITY; FATIGUE; FATIGUE ASSOCIATED WITH DEPRESSION QUESTIONNAIRE; FEMALE; FOLLOW UP; GENERALIZED ANXIETY DISORDER SCALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PAIN; PROSPECTIVE STUDY; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY; RETROSPECTIVE STUDY; SLEEP DISORDER; SOCIAL STATUS; TREATMENT DURATION; ALCOHOLISM; DEPRESSIVE DISORDER; ECONOMICS; MIDDLE AGED; SLEEP INITIATION AND MAINTENANCE DISORDERS; SOCIAL CLASS; UNITED STATES;

ADULT; ALCOHOLISM; ANXIETY; COMORBIDITY; DEPRESSION; DEPRESSIVE DISORDER; FATIGUE; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PAIN; RETROSPECTIVE STUDIES; SLEEP INITIATION AND MAINTENANCE DISORDERS; SOCIAL CLASS; UNITED STATES;

EID: 84929262534     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2014.08.003     Document Type: Article

References (33)

1. Kessler R.C., Berglund P., Demler O., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). J Am Med Assoc 2003, 289(23):3095-3105.
2. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62(6):617-627.
3. Greenberg P.E., Kessler R.C., Birnbaum H.G., et al. The economic burden of depression in the United States: how did it change between 1990 and 2000?. J Clin Psychiatry 2003, 64(12):1465-1475.
4. Korszun A., Moskvina V., Brewster S., et al. Familiality of symptom dimensions in depression. Arch Gen Psychiatry 2004, 61(5):468-474.
5. Arnold L.M. Understanding fatigue in major depressive disorder and other medical disorders. Psychosomatics 2008, 49(3):185-190.
6. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2013, American Psychiatric Association, Arlington, VA, (accessed June 1, 2013). http://dsm.psychiatryonline.org, 5th ed.
7. Greco T., Eckert G., Kroenke K. The outcome of physical symptoms with treatment of depression. J Gen Intern Med 2004, 19(8):813-818.
8. Berman R.M., Narasimhan M., Miller H.L., et al. Transient depressive relapse induced by catecholamine depletion. Arch Gen Psychiatry 1999, 56:395-403.
9. Stah S.M., Zhang L., Damatarca C., Grady M. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry 2003, 64:6-17.
10. International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (IACFS/ME) Chronic fatigue syndrome/myalgic encephalomyelitis. A primer for clinical practitioners 2014, International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (IACFS/ME), Chicago, IL.
11. Nierenberg A.A., Husain M.M., Trivedi M.H., et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2010, 40(1):41-50.
12. McClintock S.M., Husain M.M., Wisniewski S.R., et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol 2011, 31(2):180-186.
13. Fava M., Graves L.M., Benazzi F., et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 2006, 67(11):1754-1759.
14. Daly E.J., Trivedi M.H., Fava M., et al. The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study. J Clin Psychopharmacol 2011, 31(1):31-38.
15. Carter G.C., Cantrell R.A., Zarotsky V., et al. Comprehensive review of factors implicated in the heterogeneity of treatment response in depression. Depress Anxiety 2012, 29(4):340-354.
16. Swindle R., Kroenke K., Braun L. Energy and improved workplace productivity in depression. Investing in Health: The Social and Economic Benefits of Health Care Innovation 2001, 323-341. Emerald Group Publishing, United Kingdom. I. Farquhar, A. Sorkin, K. Summers (Eds.).
17. Goldberg D.B. Manual of the General Health Questionnaire 1978, NFER Publishing, Windsor, England.
18. Matza L.S., Phillips G.A., Revicki D.A., Murray L., Malley K.G. Development and validation of a patient-report measure of Fatigue Associated with Depression. J Affect Disord 2011, 134(1-3):294-303.
19. Matza L.S., Wyrwich K.W., Phillips G.A., Murray L.T., Malley K.G., Revicki D.A. The Fatigue Associated with Depression Questionnaire (FAsD): responsiveness and responder definition. Qual Life Res 2013, 22(2):351-360.
20. Rush A.J., Trivedi M.H., Ibrahim H.M., et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS) Clinician Rating (QIDS-C) and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003, 54(5):573-583.
21. Kroenke K., Spitzer R.L., Williams J.B.W., Monahan P.O., Lowe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007, 146:317-325.
22. Soldatos C.R., Dikeos D.G., Paparrigopoulos T.J. The diagnostic validity of the Athens Insomnia Scale. J Psychosom Res 2003, 55(3):263-267.
23. Atkinson T.M., Mendoza T.R., Sit L., et al. The Brief Pain Inventory and its "Pain at its Worst in the last 24 Hours" item: clinical trial endpoint considerations. Pain Med 2010, 11(3):337-346.
24. Dawson D., Pulay A.J., Grant B.F. A comparison of two single-item screeners for hazardous drinking and alcohol use disorder. Alcohol Clin Exp Res 2010, 34(2):364-374.
25. Quan H., Sundararajan V., Halfon P., et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005, 43(11):1130-1139.
26. Karve S., Cleve M.A., Helm M., Hudson T.J., West D.S., Martin B.C. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009, 25(9):2303-2310.
27. Chernick M.R. Bootstrap Methods: A Guide for Practitioners and Researchers 1999, John Wiley & Sons, Inc, Hoboken, New Jersey.
28. ® 2010, SAS Institute Inc, Cary, NC.
29. Lunceford J.K., Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004, 23(19):2937-2960.
30. Addington A.M., Gallo J.J., Ford D.E., Eaton W.W. Epidemiology of unexplained fatigue and major depression in the community: the Baltimore ECA follow-up, 1981-1994. Psychol Med 2001, 31(6):1037-104431.
31. White P.D., Goldsmith K.A., Johnson A.L., et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet 2011, 377:823-836.
32. Brown L.F., Rand K.L., Bigatti S.M., et al. Longitudinal relationships between fatigue and depression in cancer patients with depression and/or pain. Health Psychol 2013, 32(12):1199-1208.
33. Spettell C.M., Wall T.C., Allison J., et al. Identifying physician-recognized depression from administrative claims data: consequences for quality measurement. Health Serv Res 2003, 38(4):1082-1102.